Pre-market ISRG stock $494.02 on NASDAQ: model suggests +21.91% yearly upside
We start pre-market with ISRG stock trading at $494.02 on the NASDAQ in the United States. The company shows solid growth but a rich valuation, with EPS $7.89 and P/E 62.61. Volume sits at 1,404,684 versus an average of 1,865,776. We review fundamentals, technicals, analyst targets and model forecasts to frame near-term AI-driven buying interest.
ISRG stock pre-market snapshot and price action
ISRG stock opened at $489.69 and sits at $494.02 in pre-market trading on NASDAQ. The intraday range is $487.51–$496.27 and the 52-week range is $425.00–$603.88. Recent share movement shows a 1‑day change of +0.39% and year-to-date decline of -12.09%.
ISRG stock fundamentals and valuation
Intuitive Surgical, Inc. (ISRG) trades at a high multiple with P/E 62.61 and price-to-sales ~17.42. Cash per share is $16.72 and book value per share is $50.55, giving a price-to-book near 9.83. Free cash flow yield is low at ~1.42%, reflecting premium growth pricing.
ISRG stock earnings, guidance and analyst price targets
ISRG beat Q4 estimates with revenue strength and a push from da Vinci 5 placements, yet margins softened. Wall Street targets range from $620.00 to $750.00, with a MarketBeat average near $617.23. The broker mix shows 16 Buys, 4 Holds, 2 Sells, signaling positive analyst sentiment overall.
ISRG stock technicals and trading signals
Short-term momentum is neutral with RSI 41.53 and MACD histogram positive at 3.21. The 50-day average is $536.63 and the 200-day average is $515.49, placing price below both averages. Bollinger bands center at $495.49, suggesting consolidation and lower volatility ahead.
ISRG stock risks and AI-era opportunities
Sustained growth depends on system placements, utilization and OUS budget recovery; Medicaid policy and tariffs are downside risks. AI and data-enabled products like Case Insights could raise utilization and service revenue, creating long-term upside if adoption widens.
Meyka AI rates ISRG with a score out of 100
Meyka AI rates ISRG with a score of 79.76 out of 100 (B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. The grade reflects strong cash generation and growth, offset by premium valuation. These grades are informational only and are not investment advice.
Final Thoughts
We see ISRG stock as a high-quality healthcare growth name trading at a premium. Fundamentals show durable revenue and free cash flow, but the P/E 62.61 and price-to-sales 17.42 demand continued execution. Analysts place targets mostly above current price, and Meyka AI’s forecast model projects a yearly price of $602.22, implying +21.91% upside versus the current $494.02. Technicals show consolidation under the 50‑day average, so traders should watch utilization, system placements and margin trends for directional cues. Meyka AI, an AI-powered market analysis platform, flags ISRG as a BUY on a 0–100 scale but emphasizes valuation and policy risks. Forecasts are model-based projections and are not guarantees.
FAQs
What is the current ISRG stock price and valuation?
ISRG stock is trading at $494.02 pre-market on NASDAQ. Key metrics include EPS $7.89, P/E 62.61, and market cap about $175.44 billion in USD.
What does Meyka AI forecast for ISRG stock?
Meyka AI’s forecast model projects a yearly price of $602.22, implying +21.91% upside from the current $494.02. Forecasts are model-based projections and not guarantees.
What are the main risks affecting ISRG stock?
Primary risks include high valuation, margin pressure from tariffs and costs, OUS budget limits, and potential Medicaid policy changes that could impact procedure volumes and reimbursement.
Which analysts and price targets should investors watch?
Notable targets include Truist $650.00, Sanford Bernstein $750.00, Barclays $712.00, and a MarketBeat average near $617.23. The consensus leans toward Buy among brokerage coverage.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.